​

Tyra Biosciences Stock (NASDAQ:TYRA)

ForecastOwnershipFinancialsChart
Tyra Biosciences by TradingView

Previous Close

$36.54

52W Range

$6.42 - $36.59

50D Avg

$30.69

200D Avg

$18.03

Market Cap

$1.93B

Avg Vol (3M)

$844.37K

Beta

1.06

Div Yield

-

TYRA Company Profile

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

60

IPO Date

Sep 15, 2021

Website

TYRA Performance

TYRA Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-132.76M$-104.18M$-79.94M
Net Income$-119.95M$-86.48M$-69.13M
EBITDA$-132.76M$-103.66M$-79.59M
Basic EPS$-2.01$-1.51$-1.62
Diluted EPS$-2.01$-1.51$-1.62

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
EYPTEyePoint Pharmaceuticals, Inc.
NBTXNanobiotix S.A.
KURAKura Oncology, Inc.
DAWNDay One Biopharmaceuticals, Inc.
RZLTRezolute, Inc.
PRMEPrime Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
PROKProKidney Corp.
SVRASavara Inc.
GERNGeron Corporation